Overview

Study to Assess the Efficacy of Anti-Bet v 1 Monoclonal Antibodies in Adults to Reduce Symptoms of Seasonal Allergic Rhinitis

Status:
Completed
Trial end date:
2021-08-24
Target enrollment:
Participant gender:
Summary
The primary objective is to assess the reduction of allergic symptoms as measured by combined symptom and medication score (CSMS) during birch pollen season after a single dose of REGN5713-5714-5715 versus placebo.
Phase:
Phase 3
Details
Lead Sponsor:
Regeneron Pharmaceuticals